Why I’m avoiding these 3 FTSE 100 stocks in 2020

G A Chester sees different issues with these three FTSE 100 (INDEXFTSE:UKX) stocks, but valuations are the acid test.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are a number of FTSE 100 stocks I think could disappoint investors in 2020. Among them are AstraZeneca (LSE: AZN), St. James’s Place (LSE: STJ) and Scottish Mortgage Investment Trust (LSE: SMT). Here’s why I’m avoiding these three.

Dubious core strength

AstraZeneca’s management has maintained the core earnings per share (EPS) guidance it gave at the start of the year of $3.50-$3.70 for 2019. At the midpoint and current exchange rates, this gives a price-to-earnings (P/E) ratio of 26.5 at a share price of 7,300p.

This is a huge premium to Footsie pharma peers GlaxoSmithKline and Hikma Pharmaceuticals, which trade at P/Es of 14.4 and 17.7 respectively. Furthermore, I’d argue AZN’s core EPS, on which the 26.5 P/E is based, grossly overstates its real core earnings, and that the true P/E is nearer a jaw-dropping 40.

This is because I exclude one-off profits from the divestment of non-core assets, which can’t go on forever but which AZN books as core operating profit. I also include legal costs (a routine expense in operating a big pharma company), which AZN excludes. AZN looks overvalued to me on its own core EPS measure, but grossly overvalued on what I consider its true core earnings.

Iffy business model

I’m avoiding wealth manager St. James’s Place on a view that it’s not only overvalued, but also has an iffy business model, and will have to change, with profit-margin-sapping consequences.

At a share price of around 1,100p, STJ’s P/E is 32.4 on forecast EPS of 34p for 2019. This earnings multiple is far too high, in my opinion. Furthermore, a valuation of more than 3% of funds under management (FUM) has proved a trusty indicator of overvaluation, in my experience. With a market capitalisation of £5.88bn, and FUM of £112.82bn, STJ is valued at 5.2% of FUM.

The company’s management fees and exit fees are excessive, in my view. Investors haven’t worried too much about this, seeing their portfolios increase in value over the last 10 years of rising markets, but are likely to pay a lot more attention in a downturn. Furthermore, with investors generally becoming a lot savvier about the corrosive effect of fees on returns, I think STJ will ultimately have to reset its margins.

Bonkers

It’s a peculiar and persistent feature of the UK stock market that some investment trust or another will rise from the FTSE 250 to the FTSE 100. However, no trust in history has gained sufficient critical mass to maintain its position in the top index.

Scottish Mortgage is the current representative in the FTSE 100. It’s achieved its status by a combination of high returns (471% over the last 10 years) and increasing popularity with investors (taking its shares to a premium to net asset value (NAV)).

The company has surfed on the outperformance of the US market and tech sector, holding a number of the so-called FAANG stocks, and the likes of Illumina and Tesla. The managers of the trust have borrowed money to gear returns (gearing is currently 9%), and remain optimistic on the outlook.

Personally, I think the valuations of many of the underlying holdings are bonkers. I fear a de-rating, SMT’s NAV dropping, gearing working negatively, and the shares moving to a wide discount to NAV. If so, SMT will become another in the long history of investment trusts failing to maintain a place in the FTSE 100.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline and Tesla. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£10,000 buys 373 shares in this FTSE 100 heavyweight that’s tipped to surve in 2026

With analysts expecting the stock to climb 54% in the next 12 months, is now the perfect time for investors…

Read more »

This way, That way, The other way - pointing in different directions
Investing Articles

Are BP shares a slam-dunk buy as oil prices rocket – or is there a hidden danger?

As the oil price rises, investors might expect BP shares to follow. But Harvey Jones warns it may not play…

Read more »

Investing Articles

2 growth stocks to consider buying for an ISA in March

Here are two growth stocks I think are worth considering buying. Both have stumbled recently, even though the underlying businesses…

Read more »

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Investing Articles

How long might a Stocks and Shares ISA take to earn a £950 monthly second income?

Christopher Ruane explains how someone could seek to turn a Stocks and Shares ISA into a source of monthly passive…

Read more »

British pound data
Investing Articles

Get yourself ready for a violent stock market crash!

The FTSE 100 is sinking, raising fears of a fresh stock market crash. What are you doing about it? Here's…

Read more »

ISA Individual Savings Account
Investing Articles

Hands up, who’s dreaming of a million in a Stocks and Shares ISA?

How to make a million in a Stocks and Shares ISA, that's what headlines keep banging on about. Let's look…

Read more »

British Pennies on a Pound Note
Investing Articles

OK, who’s dreaming of making a million from red-hot penny shares?

Investors in penny shares can sound like the most upbeat optimists there are. It can work, but hopes need to…

Read more »

Three generation family are playing football together in a field. There are two boys, their father and their grandfather.
Investing Articles

Could this ultra-high-yielding FTSE 100 passive income gem quietly fund my retirement?

With rising payouts, strong cash generation and impressive earnings forecasts, this FTSE 100 dividend gem may be developing into a…

Read more »